Loading organizations...
§ Private Profile · Emeryville, CA, USA
biotechnology company developing T-cell immunotherapies for oncology, focused on solid tumors like liver cancer.
Founded in 2006 by CEO Cheng Liu, Eureka Therapeutics is an Emeryville, California-based biotechnology company developing proprietary T-cell immunotherapies targeting solid tumors and other cancer cells. The organization advances clinical-stage oncology programs from initial discovery through human trials, maintaining a specific therapeutic emphasis on treating patients diagnosed with liver cancer. Operating as a venture-backed enterprise, the firm previously secured $21 million in Series C financing led by Yuan Capital, alongside Acorn Pacific Ventures and Harbinger Venture Capital, supporting its proprietary antibody platforms. The company's executive leadership includes Chief Operating Officer Vivien Chan, while its board of directors features notable industry figures like Lewis Rusty Williams and Chih-Kai Cheng. Recently, the enterprise further expanded its corporate governance structure by appointing executives Reginald Seeto and William Solari III to its board of directors on August 12, 2025.
Eureka Therapeutics has raised $132.0M across 4 funding rounds.
Eureka Therapeutics has raised $132.0M in total across 4 funding rounds.
Eureka Therapeutics has raised $132.0M across 4 funding rounds. Most recently, it raised $45.0M Series E in March 2020.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Mar 17, 2020 | $45M Series E | Richard Klausner | — | Announced |
| Jan 23, 2018 | $60M Series D | C.k. Cheng | GP Capital | Announced |
| Sep 23, 2014 | $21M Series C | Yuan Capital | — | Announced |
| Nov 17, 2008 | $6M Venture Round | Harbinger Venture Management | Acorn Campus, Desert Spring Life Science Capital | Announced |
Eureka Therapeutics has raised $132.0M in total across 4 funding rounds.
Eureka Therapeutics's investors include Richard Klausner, C.K. Cheng, GP Capital, Yuan Capital, Harbinger Venture Management, Acorn Campus, Desert Spring Life Science Capital.